Drug Trial Radar · NCT07862725
Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled Trial
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Oct 15, 2027
Study completion Oct 15, 2028
Sponsor
- Lead sponsor
- Hamad Medical CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 21 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective randomized controlled trial will compare three treatment approaches for men with idiopathic oligoasthenoteratozoospermia (OAT), a condition characterized by abnormalities in sperm count, movement, and shape without an identified cause. Participants will be randomly assigned in a 1:1:1 ratio to receive antioxidant therapy alone, antioxidant therapy plus clomiphene citrate, or antioxidant therapy plus follicle-stimulating hormone (FSH) for 6 months. The study will evaluate whether adding clomiphene citrate or FSH to antioxidant therapy improves semen parameters compared with antioxidant therapy alone. The main outcomes will include changes in sperm concentration, motility, and morphology. The study will also assess sperm function, hormonal changes, treatment adherence, and adverse events.
Conditions
- Oligoasthenoteratozoospermia
- Male Infertility
Interventions
Antioxidants + Clomiphene CitrateDrug
Participants will receive the same antioxidant regimen as the active comparator arm plus clomiphene citrate 50 mg orally every other day for 6 months.
Antioxidants + FSHDrug
Participants will receive the same antioxidant regimen plus FSH 150 IU administered subcutaneously three times weekly for 6 months.
Antioxidants AloneDrug
Participants will receive antioxidant therapy consisting of vitamin C 1000 mg/day, vitamin E 400 IU/day, L-carnitine, and zinc 25 mg/day for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Sperm ConcentrationTime frame: Baseline and 6 months
- Change in Sperm MotilityTime frame: Baseline and 6 months
- Change in Sperm MorphologyTime frame: from baseline to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ambulatory Care Center (ACC), Hamad Medical Corporation
Doha, Baladiyat ad Dawhah, Qatar
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.